BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

604 related articles for article (PubMed ID: 28764328)

  • 1. Protospacer Adjacent Motif-Induced Allostery Activates CRISPR-Cas9.
    Palermo G; Ricci CG; Fernando A; Basak R; Jinek M; Rivalta I; Batista VS; McCammon JA
    J Am Chem Soc; 2017 Nov; 139(45):16028-16031. PubMed ID: 28764328
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Conformational control of DNA target cleavage by CRISPR-Cas9.
    Sternberg SH; LaFrance B; Kaplan M; Doudna JA
    Nature; 2015 Nov; 527(7576):110-3. PubMed ID: 26524520
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DNA interrogation by the CRISPR RNA-guided endonuclease Cas9.
    Sternberg SH; Redding S; Jinek M; Greene EC; Doudna JA
    Nature; 2014 Mar; 507(7490):62-7. PubMed ID: 24476820
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bidirectional Degradation of DNA Cleavage Products Catalyzed by CRISPR/Cas9.
    Stephenson AA; Raper AT; Suo Z
    J Am Chem Soc; 2018 Mar; 140(10):3743-3750. PubMed ID: 29461055
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cas9, Cpf1 and C2c1/2/3-What's next?
    Nakade S; Yamamoto T; Sakuma T
    Bioengineered; 2017 May; 8(3):265-273. PubMed ID: 28140746
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition Mechanism of an Anti-CRISPR Suppressor AcrIIA4 Targeting SpyCas9.
    Yang H; Patel DJ
    Mol Cell; 2017 Jul; 67(1):117-127.e5. PubMed ID: 28602637
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Leveraging QM/MM and Molecular Dynamics Simulations to Decipher the Reaction Mechanism of the Cas9 HNH Domain to Investigate Off-Target Effects.
    Maghsoud Y; Jayasinghe-Arachchige VM; Kumari P; Cisneros GA; Liu J
    J Chem Inf Model; 2023 Nov; 63(21):6834-6850. PubMed ID: 37877218
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structural Basis for the Canonical and Non-canonical PAM Recognition by CRISPR-Cpf1.
    Yamano T; Zetsche B; Ishitani R; Zhang F; Nishimasu H; Nureki O
    Mol Cell; 2017 Aug; 67(4):633-645.e3. PubMed ID: 28781234
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Programmable RNA recognition and cleavage by CRISPR/Cas9.
    O'Connell MR; Oakes BL; Sternberg SH; East-Seletsky A; Kaplan M; Doudna JA
    Nature; 2014 Dec; 516(7530):263-6. PubMed ID: 25274302
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cas9 specifies functional viral targets during CRISPR-Cas adaptation.
    Heler R; Samai P; Modell JW; Weiner C; Goldberg GW; Bikard D; Marraffini LA
    Nature; 2015 Mar; 519(7542):199-202. PubMed ID: 25707807
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CRISPR-Cas9 Structures and Mechanisms.
    Jiang F; Doudna JA
    Annu Rev Biophys; 2017 May; 46():505-529. PubMed ID: 28375731
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Real-time observation of DNA target interrogation and product release by the RNA-guided endonuclease CRISPR Cpf1 (Cas12a).
    Singh D; Mallon J; Poddar A; Wang Y; Tippana R; Yang O; Bailey S; Ha T
    Proc Natl Acad Sci U S A; 2018 May; 115(21):5444-5449. PubMed ID: 29735714
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Methods for decoding Cas9 protospacer adjacent motif (PAM) sequences: A brief overview.
    Karvelis T; Gasiunas G; Siksnys V
    Methods; 2017 May; 121-122():3-8. PubMed ID: 28344037
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structures of a CRISPR-Cas9 R-loop complex primed for DNA cleavage.
    Jiang F; Taylor DW; Chen JS; Kornfeld JE; Zhou K; Thompson AJ; Nogales E; Doudna JA
    Science; 2016 Feb; 351(6275):867-71. PubMed ID: 26841432
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Programmable DNA cleavage in vitro by Cas9.
    Karvelis T; Gasiunas G; Siksnys V
    Biochem Soc Trans; 2013 Dec; 41(6):1401-6. PubMed ID: 24256227
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Probing the structural dynamics of the CRISPR-Cas9 RNA-guided DNA-cleavage system by coarse-grained modeling.
    Zheng W
    Proteins; 2017 Feb; 85(2):342-353. PubMed ID: 27936513
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structural Basis for Reduced Dynamics of Three Engineered HNH Endonuclease Lys-to-Ala Mutants for the Clustered Regularly Interspaced Short Palindromic Repeat (CRISPR)-Associated 9 (CRISPR/Cas9) Enzyme.
    Wang J; Skeens E; Arantes PR; Maschietto F; Allen B; Kyro GW; Lisi GP; Palermo G; Batista VS
    Biochemistry; 2022 May; 61(9):785-794. PubMed ID: 35420793
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CRISPR/Cas9 for genome editing: progress, implications and challenges.
    Zhang F; Wen Y; Guo X
    Hum Mol Genet; 2014 Sep; 23(R1):R40-6. PubMed ID: 24651067
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Engineered CRISPR-Cas9 nucleases with altered PAM specificities.
    Kleinstiver BP; Prew MS; Tsai SQ; Topkar VV; Nguyen NT; Zheng Z; Gonzales AP; Li Z; Peterson RT; Yeh JR; Aryee MJ; Joung JK
    Nature; 2015 Jul; 523(7561):481-5. PubMed ID: 26098369
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An engineered ScCas9 with broad PAM range and high specificity and activity.
    Chatterjee P; Jakimo N; Lee J; Amrani N; Rodríguez T; Koseki SRT; Tysinger E; Qing R; Hao S; Sontheimer EJ; Jacobson J
    Nat Biotechnol; 2020 Oct; 38(10):1154-1158. PubMed ID: 32393822
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.